Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 836826 + venetoclax
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (bi 836826), Oral (venetoclax)
01
Overview
BI 836826 + venetoclax is a combination investigational regimen consisting of BI 836826, a chimeric IgG1 monoclonal antibody targeting CD37 (a transmembrane protein highly expressed on normal and malignant B-cells), and venetoclax, a small molecule inhibitor of B-cell lymphoma-2 (BCL-2). BI 836826 activates both antibody-dependent cell-mediated cytotoxicity and has intrinsic proapoptotic activity against malignant B cells, while venetoclax selectively inhibits BCL-2, restoring apoptosis in chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The combination is being studied primarily in patients with relapsed/refractory CLL, aiming to achieve synergistic clearance of malignant B cells and higher rates of complete remission and minimal residual disease negativity compared to single-agent or alternative regimens[1][3][4][9].
- Brand names
- Venclexta (for venetoclax)
- Other names
- BI 836826 + venetoclax
02
Targets
BCL-2 (BCL-2 family)CD37
Beyond the preview
Go deeper on BI 836826 + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 836826 + venetoclax.